Strategic Partnership Between PRA International and Geriatric Oncology Consortium, Inc. Proves Successful
Alliance Creates Powerful Oncology Research Synergies
(RESTON, VA, May 4, 2005) -- /PRNewswire- FirstCall via COMTEX / PRA International [NASDAQ: PRAI], one of the world's leading clinical research organizations (CROs), today announced the first successful outcome resulting from a strategic alliance formed with the Geriatric Oncology Consortium (GOC), a non-profit organization and leading provider of community-based geriatric oncology research and education.
A collaborative effort between PRA and GOC resulted in the successful completion of a large multi-center clinical trial.
Patrick Donnelly, President and CEO of PRA, said this success demonstrates how the mutually beneficial partnership enhances the overall quality and efficiency of oncology trials for PRA, GOC and their clients.
"The completion of this trial is proof that by combining resources, both organizations significantly increase the strength of their oncology research capabilities," said Mr. Donnelly. "The GOC's tremendous scientific expertise in gero-oncology and its investigator network enables PRA to further expand relationships within the domestic oncology research community and gain access to patients that meet our sponsors' geriatric oncology trial requirements."
Jody Simon, Chief Executive Officer of the GOC, was also pleased with the results of the endeavor.
"It is exciting to see this partnership produce positive results so early in the relationship," said Mr. Simon. "We believe this is just the beginning of many projects and trials that we will conduct with PRA demonstrating the joint abilities of our organizations to accrue patients rapidly into oncology trials designed specifically for the elderly population."
The GOC and PRA are working collaboratively on several projects. The most exciting project is in early stages of development involving a registry program for the older adult cancer population. Due to the increased number of innovative products on the market and in the drug development pipeline, and the increase in the older adult with cancer population, PRA and GOC have identified the need to explore the long-term impact of these products in this growing population.
The continued partnership adds to PRA's growing domestic oncology expertise. Oncology trials currently represent PRA's largest therapeutic area; the company is currently conducting oncology trials at approximately 3,000 sites on a global basis. # # #
Geriatric Oncology Consortium
The GOC is a national non-profit organization tasked with the mission to be the premier provider and resource for geriatric oncology research and education, and to fill the urgent need to address cancer treatment in the elderly through a national, community-based program. The GOC also conducts patient and caregiver educational programs to educate and enhance clinical trial participation among older adults with cancer. For more information please visit www.thegoc.org.
PRA International
PRA International is one of the world's leading clinical development organizations, with over 2,500 employees working from offices in North America, Europe, South America, Africa, Australia and Asia. PRA delivers services to its clients through a unique approach called Project AssuranceSM, which represents the Company's commitment to reliable service delivery, program-level therapeutic expertise, easy global access to knowledge and involved senior management.
To learn more about the Geriatric Oncology Consortium, visit www.thegoc.org or call 410-467-3600 x 225.
To learn more about PRA International, please visit www.prainternational.com or call our World Headquarters at +1 (703) 464-6300.
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
FDA-Approved Gene Therapy Beqvez Shows Sustained Efficacy, Safety in Long-Term Hemophilia B Trial
April 17th 2025Beqvez (fidanacogene elaparvovec), an FDA-approved one-time gene therapy for hemophilia B, demonstrated sustained factor IX expression, low bleeding rates, and a favorable safety profile over long-term follow-up.
